Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis.
BACKGROUND
Leptin regulates food intake and modulates immunity and inflammation. A positive feedback mechanism has been described between tumour necrosis factor (TNF) and leptin, and it has been suggested that leptin potentiates inflammation in patients with rheumatoid arthritis (RA).


OBJECTIVE
To assess whether inflammation correlates with leptin concentrations in patients with RA, and whether anti-TNF treatment modulates leptin concentrations in these patients.


METHODS
Leptin, IL6 and CRP were measured (at baseline and after 2 weeks of treatment) in the blood of 31 patients with RA starting either anti-TNF treatment or placebo, and in 18 healthy controls.


RESULTS
In patients with RA, plasma leptin concentrations at baseline correlated inversely with the degree of inflammation as assessed by C reactive protein (CRP; r(s)(2) = 0.21, p<0.01) or interleukin (IL) 6 concentrations (r(s)(2) = 0.22, p<0.008). Mean (SD) leptin concentrations did not differ between patients with RA and controls (6.0 (4.6) v 4.2 (2.8) ng/ml in men; 15.1 (7.9) v 13.4 (5.2) ng/ml in women). Short course anti-TNF treatment for 2 weeks did not modify leptin concentrations, despite significant reduction of CRP and IL6.


CONCLUSIONS
A significant inverse correlation between inflammation and leptin concentrations was found in patients with active RA, although plasma leptin concentrations did not significantly differ from those in healthy controls. This suggests that active chronic inflammation may lower plasma leptin concentrations. Two weeks' treatment with anti-TNF did not change plasma leptin concentrations and longer treatment may be needed to see an effect on leptin.
Popa
C
C
Department of Internal Medicine, University Medical Centre St Radboud, PO Box 9101, 6500HB Nijmegen, The Netherlands.
Netea
M G
MG
Radstake
T R D S
TR
van Riel
P L
PL
Barrera
P
P
van der Meer
J W M
JW
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood; D018836:Inflammation Mediators / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015415:Biomarkers; D018836:Inflammation Mediators; D015850:Interleukin-6; D020738:Leptin; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D000068879:Adalimumab
Ann Rheum Dis. 2005 Feb;64(2):303-5
15231512
J Clin Endocrinol Metab. 1999 Oct;84(10):3686-95
10523015
Annu Rev Physiol. 2000;62:413-37
10845097
FASEB J. 2001 Dec;15(14):2565-71
11726531
J Immunol. 2002 Jan 15;168(2):875-82
11777985
J Clin Endocrinol Metab. 2002 Feb;87(2):758-63
11836317
Rinsho Byori. 2002 May;50(5):524-7
12078053
Pol Arch Med Wewn. 2002 Aug;108(2):761-7
12476896
Arthritis Rheum. 2003 Feb;48(2):404-9
12571850
Ann Rheum Dis. 2003 Oct;62(10):952-6
12972473
Ann Rheum Dis. 2004 Jul;63(7):809-16
15194576
Br Med J (Clin Res Ed). 1985 Jun 15;290(6484):1797-9
3924262
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8374-8
8710878
J Clin Endocrinol Metab. 1998 Jan;83(1):280-3
9435456
FASEB J. 1998 Jan;12(1):57-65
9438411
Metabolism. 1999 Jun;48(6):745-8
10381149
J Infect Dis. 1999 Sep;180(3):908-11
10438392
Endocrinology. 2005 Mar;146(3):1491-7
15564333